12 US IPOs planned for the week of Jul 22

The following IPOs are expected to price this week:

Agios Pharmaceuticals (AGIO), a biotech developing metabolic treatments for cancer and rare genetic diseases, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Agios Pharmaceuticals would command a market value of $441 million. Agios Pharmaceuticals, which was founded in 2007, booked $25 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol AGIO. J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal.

Cellular Dynamics International (ICEL), which develops and manufactures functioning human cells in large quantities, plans to raise $50 million by offering 3.8 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Cellular Dynamics International would command a market value of $212 million. Cellular Dynamics International, which was founded in 2004, booked $8 million in sales over the last 12 months. The Madison, WI-based company plans to list on the NASDAQ under the symbol ICEL. is the lead bookrunner on the deal.

Conatus Pharmaceuticals (CNAT), a biotech developing treatments for chronic liver disease, plans to raise $55 million by offering 5.0 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Conatus Pharmaceuticals would command a market value of $160 million. Conatus Pharmaceuticals was founded in 2005. The San Diego, CA-based company plans to list on the NASDAQ under the symbol CNAT. Stifel and Piper Jaffray are the joint bookrunners on the deal.

Graña y Montero (GRAM), the largest engineering and construction company in Peru, plans to raise $350 million by offering 16.3 million shares at a price range of $19.70 to $23.30. At the midpoint of the proposed range, Graña y Montero would command a market value of $2.8 billion. Graña y Montero, which was founded in 1933, booked $2.0 billion in sales over the last 12 months. The Lima, Peru-based company plans to list on the NYSE under the symbol GRAM. Credit Suisse, J.P. Morgan, Morgan Stanley and BTG Pactual are the joint bookrunners on the deal.Please note: Shares already trade on the Lima Stock Exchange under ticker GRAMONC1.

Heat Biologics (HTBX), which is developing cellular therapeutic vaccines for cancer therapy, plans to raise $25 million by offering 2.3 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Heat Biologics would command a market value of $64 million. Heat Biologics, which was founded in 2008, booked $0 million in sales over the last 12 months. The Chapel Hill, NC-based company plans to list on the NASDAQ under the symbol HTBX. is the lead bookrunner on the deal.

Jones Energy (JONE), a oil and gas E&P focused on the Anadarko and Arkoma basins of TX and OK, plans to raise $252 million by offering 14.0 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Jones Energy would command a market value of $915 million. Jones Energy, which was founded in 1988, booked $191 million in sales over the last 12 months. The Austin, TX-based company plans to list on the NYSE under the symbol JONE. J.P. Morgan, Barclays and Wells Fargo Securities are the joint bookrunners on the deal.

Liquid Holdings Group (LIQD), which provides an integrated software platform for hedge funds and asset managers, plans to raise $50 million by offering 5.0 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Liquid Holdings Group would command a market value of $269 million. Liquid Holdings Group, which was founded in 2012, booked $4 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol LIQD. is the lead bookrunner on the deal.

Marlin Midstream Partners LP (FISH), a spark Energy-affiliated LP formed to own midstream energy assets, plans to raise $125 million by offering 6.3 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Marlin Midstream Partners LP would command a market value of $356 million. Marlin Midstream Partners LP, which was founded in 2013, booked $48 million in sales over the last 12 months. The Houston, TX-based company plans to list on the NASDAQ under the symbol FISH. Stifel, Baird and Oppenheimer & Co. are the joint bookrunners on the deal.

Onconova Therapeutics (ONTX), a biotech focused on developing drug candidates for cancer and related diseases, plans to raise $60 million by offering 4.6 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Onconova Therapeutics would command a market value of $261 million. Onconova Therapeutics, which was founded in 1998, booked $47 million in sales over the last 12 months. The Newtown, PA-based company plans to list on the NASDAQ under the symbol ONTX. Citi and Leerink Swann are the joint bookrunners on the deal.

Phillips 66 Partners LP (PSXP), which phillips 66-backed limited partnership that owns pipeline and logistics assets, plans to raise $300 million by offering 15.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Phillips 66 Partners LP would command a market value of $1.4 billion. Phillips 66 Partners LP, which was founded in 2012, booked $118 million in sales over the last 12 months. The Houston, TX-based company plans to list on the NYSE under the symbol PSXP. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal.

Silver Eagle Acquisition (EAGLU), a blank check company focused on acquiring businesses in the media and entertainment industry, plans to raise $250 million by offering 25.0 million shares at a price range of $10.00 to $10.00. At the midpoint of the proposed range, Silver Eagle Acquisition would command a market value of $313 million. Silver Eagle Acquisition was founded in 2013. The Santa Monica, CA-based company plans to list on the NASDAQ under the symbol EAGLU. is the lead bookrunner on the deal.

WCI Communities (WCIC), which develops luxury residential communities and homes in coastal Florida, plans to raise $185 million by offering 8.4 million shares at a price range of $21.00 to $23.00. At the midpoint of the proposed range, WCI Communities would command a market value of $568 million. WCI Communities, which was founded in 1946, booked $262 million in sales over the last 12 months. The Bonita Springs, FL-based company plans to list on the NYSE under the symbol WCIC. Citi, Credit Suisse and J.P. Morgan are the joint bookrunners on the deal.

Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.

Last week, there were 7 IPO pricings. OncoMed Pharmaceuticals (OMED), a biotech developing new antibody therapeutics to be used in cancer treatments, was the week's winner, ending up 57% from its IPO price.